Literature DB >> 20028263

Comparative study of topical application of timolol and verapamil in patients with glaucoma within 6 months.

Mohammad Reza Shayegan1, Ali Akbar Boloorian, Sina Kianoush.   

Abstract

INTRODUCTION: As glaucoma is one of the most significant causes of blindness, and administration of calcium channel blockers is effective in reducing intraocular pressure (IOP) in rabbits and patients with normotensive glaucoma, we administered topical verapamil 0.25% in the human eye to compare its effect with timolol 0.5% in reducing IOP.
PURPOSE: To compare the effect of timolol 0.5% and topical verapamil 0.25% in patients with open-angle glaucoma.
METHODS: It was a double-blinded study in which 118 eyes (59 individuals) were chosen and divided into 2 groups (30 individuals related to timolol and 29 individuals related to verapamil). Patients who used drugs (systemic or topical) that could alter IOP and those with IOP <22 mmHg were excluded from the study (19 eyes). We chose patients who did not use any drugs 24 h prior to the study. Then applanation tonometry was done exactly before the administration of drugs and 90 min later and the results were compared.
RESULTS: In timolol group, mean intraocular pressure in 52 eyes (27 right eyes and 25 left eyes) decreased from 32.545 to 30.230 and mean pressure in verapamil group decreased from 33.195 to 30.835.
CONCLUSION: It seems that topical verapamil has a similar effect to timolol in patients with open-angle glaucoma, so it can be considered as a lowering intraocular pressure agent in glaucoma patients.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20028263     DOI: 10.1089/jop.2009.0005

Source DB:  PubMed          Journal:  J Ocul Pharmacol Ther        ISSN: 1080-7683            Impact factor:   2.671


  3 in total

1.  Sustained Delivery of Timolol Maleate for Over 90 Days by Subconjunctival Injection.

Authors:  Erin Lavik; Markus H Kuehn; Andrew J Shoffstall; Kristyn Atkins; Alina V Dumitrescu; Young H Kwon
Journal:  J Ocul Pharmacol Ther       Date:  2016-11-11       Impact factor: 2.671

2.  Thioredoxin interacting protein is a novel mediator of retinal inflammation and neurotoxicity.

Authors:  Mohammed M H Al-Gayyar; Mohammed A Abdelsaid; Suraporn Matragoon; Bindu A Pillai; Azza B El-Remessy
Journal:  Br J Pharmacol       Date:  2011-09       Impact factor: 8.739

Review 3.  Effect of Topical Calcium Channel Blockers on Intraocular Pressure in Steroid-induced Glaucoma.

Authors:  Sunil Ganekal; Syril Dorairaj; Vishal Jhanji; Krishnaprasad Kudlu
Journal:  J Curr Glaucoma Pract       Date:  2014-01-16
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.